BioMarin Pharmaceutical (BMRN) Stifel 2026 Healthcare Conference 2026 summary

Financial and commercial performance

• Q3 revenue grew 32% to a record $1B; metabolic conditions revenue grew 44%, while EPS and profitability also increased; two Q3 acquisitions added in-process R&D expense.

• Amicus assets drove growth: GALAFOLD patients rose 20% YoY in one market, and POMBILITI/OPFOLDA revenue grew nearly 60%.

• Identified ~$220M in non-GAAP operating expense synergies, about 50% of Amicus base operating expenses; expected full-year realization in 2028, integration mostly complete by mid-2027, and Amicus operating margin targeted at ~60% by decade-end.

Pipeline development

• BMN 440 is an oral ENPP1 inhibitor for hypophosphatasia, intended to reduce inorganic pyrophosphate; its small-molecule profile may reach muscle and joints and address symptoms beyond bone disease.

• BMN 440 development will assess distinct patient groups and endpoints in Phase II; ongoing Phase I/II work includes patients and healthy volunteers, with biochemical and PK data expected in 2027. A 30%-50% pyrophosphate reduction is the targeted range.

• BMN 450 is a mutation-agnostic Fabry enzyme replacement therapy designed for subcutaneous dosing; Phase I/II dose escalation is ongoing, with a low double-digit number of patients studied and early PK/biologic activity supporting continued testing.

• BMN 333 achondroplasia Phase II is testing three doses in 30 patients, with 10 on VOXZOGO as an internal control; readout is expected in 2027. Healthy-volunteer data showed 2-5x cyclic GMP increases at higher exposure.

• BMN 820 is an oral CCR2 inhibitor for FSGS, intended to reduce proteinuria alongside angiotensin receptor blockade; Phase III is fully enrolled and passed futility analysis, with results expected in 2028 after two years of follow-up.

Commercial outlook

• Hypochondroplasia has 14,000 addressable patients in markets with 24,000 achondroplasia patients, assuming diagnosis; diagnosis complexity is a launch headwind, while established skeletal dysplasia centers and prior launch experience are tailwinds.

• Hypochondroplasia has a May 30, 2027 PDUFA date; a potential mid-year launch could contribute mainly in H2, with 2027 guidance treatment still under consideration.